Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy : A Prospective Cohort Study
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved..
BACKGROUND: Patients with hematological cancers have increased COVID-19 morbidity and mortality, and these patients show attenuated vaccine responses. This study aimed to characterize the longitudinal humoral immune responses to COVID-19 vaccination in patients with hematological malignancies.
PATIENTS AND METHODS: We conducted a prospective cohort study, collecting samples from March 2021 to July 2022, from patients seen at a cancer treatment center in London, Ontario, Canada, who met the following eligibility criteria: age ≥18 years, diagnosed with a hematological malignancy, recipient of a COVID-19 vaccine during the study period, and able to provide informed consent.
RESULTS: Median anti-S titers (MST) were 0.0, 64.0, and 680.5 U/mL following first (V1), second (V2), and third (V3) vaccine doses, respectively. Patients with lymphoid malignancies' response to vaccination was attenuated compared to myeloid malignancy patients after V2 and V3 (P < .001, P < .01). Active treatment was associated with lower antibody titers (MST 10) compared to treatment 12-24 months (MST 465, P = .04367) and >24 months (MST 1660.5, P = .0025) prior to vaccination. V3 significantly increased antibody titers compared to V2 for patients less than 3 months from treatment. Increasing age was associated with smaller antibody response following V2 (P < .05), but not following V3. Patients receiving anti-CD20 therapy did not demonstrate increased antibody titer levels after V3 (V2 MST 0, V3 MST 0; P > .05).
CONCLUSION: We report an attenuated serologic response to COVID-19 vaccination in our study population of patients with hematological malignancy. The immune response to vaccination was affected by patient age, diagnosis, treatment, and timing of treatment exposure.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Clinical lymphoma, myeloma & leukemia - 24(2024), 5 vom: 11. Apr., Seite 305-315 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hillyer, Alexandra [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-CD20 therapy |
|---|
| Anmerkungen: |
Date Completed 25.04.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clml.2024.01.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368259897 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368259897 | ||
| 003 | DE-627 | ||
| 005 | 20240426233657.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240210s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clml.2024.01.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM368259897 | ||
| 035 | |a (NLM)38336492 | ||
| 035 | |a (PII)S2152-2650(24)00021-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hillyer, Alexandra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy |b A Prospective Cohort Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Patients with hematological cancers have increased COVID-19 morbidity and mortality, and these patients show attenuated vaccine responses. This study aimed to characterize the longitudinal humoral immune responses to COVID-19 vaccination in patients with hematological malignancies | ||
| 520 | |a PATIENTS AND METHODS: We conducted a prospective cohort study, collecting samples from March 2021 to July 2022, from patients seen at a cancer treatment center in London, Ontario, Canada, who met the following eligibility criteria: age ≥18 years, diagnosed with a hematological malignancy, recipient of a COVID-19 vaccine during the study period, and able to provide informed consent | ||
| 520 | |a RESULTS: Median anti-S titers (MST) were 0.0, 64.0, and 680.5 U/mL following first (V1), second (V2), and third (V3) vaccine doses, respectively. Patients with lymphoid malignancies' response to vaccination was attenuated compared to myeloid malignancy patients after V2 and V3 (P < .001, P < .01). Active treatment was associated with lower antibody titers (MST 10) compared to treatment 12-24 months (MST 465, P = .04367) and >24 months (MST 1660.5, P = .0025) prior to vaccination. V3 significantly increased antibody titers compared to V2 for patients less than 3 months from treatment. Increasing age was associated with smaller antibody response following V2 (P < .05), but not following V3. Patients receiving anti-CD20 therapy did not demonstrate increased antibody titer levels after V3 (V2 MST 0, V3 MST 0; P > .05) | ||
| 520 | |a CONCLUSION: We report an attenuated serologic response to COVID-19 vaccination in our study population of patients with hematological malignancy. The immune response to vaccination was affected by patient age, diagnosis, treatment, and timing of treatment exposure | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Anti-CD20 therapy | |
| 650 | 4 | |a Antibody formation | |
| 650 | 4 | |a Humoral immunity | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Vaccination response | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Quint, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Ghassemian, Artin |e verfasserin |4 aut | |
| 700 | 1 | |a Joh-Carnella, Nicolette |e verfasserin |4 aut | |
| 700 | 1 | |a Knauer, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Dawd, Danny |e verfasserin |4 aut | |
| 700 | 1 | |a Lazo-Langner, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Mangel, Joy |e verfasserin |4 aut | |
| 700 | 1 | |a Lam, Selay |e verfasserin |4 aut | |
| 700 | 1 | |a Abdoh, Husam |e verfasserin |4 aut | |
| 700 | 1 | |a Xenocostas, Anargyros |e verfasserin |4 aut | |
| 700 | 1 | |a Deotare, Uday |e verfasserin |4 aut | |
| 700 | 1 | |a Saini, Lalit |e verfasserin |4 aut | |
| 700 | 1 | |a Foster, Cheryl |e verfasserin |4 aut | |
| 700 | 1 | |a Louzada, Martha |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Jenny |e verfasserin |4 aut | |
| 700 | 1 | |a Chin-Yee, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Phua, Chai W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical lymphoma, myeloma & leukemia |d 2010 |g 24(2024), 5 vom: 11. Apr., Seite 305-315 |w (DE-627)NLM195738748 |x 2152-2669 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:5 |g day:11 |g month:04 |g pages:305-315 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clml.2024.01.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 5 |b 11 |c 04 |h 305-315 | ||